Dr. Paul Martin is Chief of the Division of Digestive Health and Liver Diseases at the Miller School of Medicine at the University of Miami where he is the Mandel Chair in Gastroenterology. He graduated from medical school at University College Dublin and was awarded a Doctorate in Medicine from the National University of Ireland. He was a resident in Internal Medicine in Dublin and at the University of Alberta, Edmonton. He trained in Gastroenterology at Queen’s University, Ontario. His hepatology training was initially at the University of Toronto followed by a Medical Staff Fellowship at the National Institutes of Health, Bethesda Maryland.

He has previously served on the Board of the American Society of Transplant and was Chair for Gastroenterology at the American Board of Internal Medicine. He served as Co-Chair on the KDIGO Guideline on management of HCV in chronic kidney disease. His involvement with AASLD has included editorship of Liver Transplantation as well serving on the Publications and Practice Guideline Committees.

Disclosures of Potential Conflicts of Interest
He has served as a consultant to AbbVie, Gilead, Merck and Mallinckrodt.

Dr. Rinella is a Professor of Medicine at University of Chicago Pritzker School of Medicine, Director of the Metabolic and Fatty Liver Program and member of the faculty at the University of Chicago Hospitals.  She received her medical degree from the University of Illinois. She completed her residency training in Internal Medicine at the University of Chicago and her fellowship in Gastroenterology and Hepatology at Northwestern University, where she remains on faculty. She studied basic mechanisms of steatohepatitis with the support of the American Gastroenterological Association and the National Institute of Health for 10 years.

Currently her focus is in clinical research in the area of non-alcoholic fatty liver disease/NASH both before and after liver transplantation. Her primary clinical focus within the NASH realm is on the associations between NASH and other metabolic co-morbidities, emerging NASH therapeutics and the recurrence of NASH after liver transplantation. She recently established a multicenter consortium to study the risk factors for liver disease recurrence and outcomes of patients transplanted for NASH cirrhosis (NailNASH Consortium).

Dr. Rinella has been actively engaged with the AASLD for many years and served in several leadership roles, including Chair of the NASH SIG, Program Evaluation Committee and most recently Chair of the NASH Task Force. She is excited to apply her enthusiasm and expertise to her new role on the AASLD Governing Board.

Disclosures of Potential Conflicts of Interest
Scientific Consulting — Intercept Pharmaceuticals, Gilead Sciences, NGM Biopharmaceuticals, Enanta, Immuron, Fractyl, Prociento, Gelesis, Merck, Bristol-Myers Squibb, Metacrine, Viking Therapeutics, Allergan, Cymabay, Boehringer Ingelheim, Genentech, Sagimet Bio, Terns, Siemens and Novartis.

Dr. Rinella has received independent research grant funding from Novartis.